US EditionPublished • loading... • Updated
Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation?
Summary by The Motley Fool
1 Articles
1 Articles
Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation?
Key PointsEli Lilly has another promising drug in its portfolio with Foundayo.Its growth rate has been more than 40% in recent quarters due to the success of its current GLP-1 drugs.The stock's valuation is high, but a premium may be warranted given its growth prospects.10 stocks we like better than Eli Lilly › The trillion-dollar club is an exclusive one, featuring some of the most successful and promising companies in the world. Joining the ra…
·Alexandria, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
